Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy.

[1]  R. Samulski,et al.  Adeno-associated virus vectors: potential applications for cancer gene therapy , 2005, Cancer Gene Therapy.

[2]  C. Barcia,et al.  Regulatable gene expression systems for gene therapy applications: progress and future challenges. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  Malika Benouchan,et al.  Anti-angiogenic strategies for cancer therapy (Review). , 2005, International journal of oncology.

[4]  M. Hitt,et al.  Transcriptionally targeted adenovirus vectors. , 2005, Current gene therapy.

[5]  Daniel W. Pack,et al.  Design and development of polymers for gene delivery , 2005, Nature Reviews Drug Discovery.

[6]  L. Rosen.  VEGF-targeted therapy: therapeutic potential and recent advances. , 2005, The oncologist.

[7]  Chryso Kanthou,et al.  Disrupting tumour blood vessels , 2005, Nature Reviews Cancer.

[8]  Roy Bicknell,et al.  Tumour vascular targeting , 2005, Nature Reviews Cancer.

[9]  S. Motl.  Bevacizumab in combination chemotherapy for colorectal and other cancers. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[10]  G. Palù,et al.  Versatility of gene therapy vectors through viruses , 2005, Expert opinion on biological therapy.

[11]  C. Qian,et al.  Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  C. Kuo,et al.  Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy , 2005, Cancer Gene Therapy.

[13]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[14]  D. Carbone,et al.  Combination Therapy with Conditionally Replicating Adenovirus and Replication Defective Adenovirus , 2004, Cancer Research.

[15]  D. Kirn,et al.  Ablating CAR and integrin binding in adenovirus vectors reduces nontarget organ transduction and permits sustained bloodstream persistence following intraperitoneal administration. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  D. Waxman,et al.  Use of Replication-Conditional Adenovirus as a Helper System to Enhance Delivery of P450 Prodrug-Activation Genes for Cancer Therapy , 2004, Cancer Research.

[17]  J. Bell,et al.  Getting oncolytic virus therapies off the ground. , 2003, Cancer cell.

[18]  I. Kuhn,et al.  Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes , 2002, Cancer Gene Therapy.

[19]  T. Hermiston.  Fighting fire with fire: attacking the complexity of human tumors with armed therapeutic viruses. , 2002, Current opinion in molecular therapeutics (Print).

[20]  P. Seth,et al.  Adenovirus replication–competent vectors (KD1, KD3) complement the cytotoxicity and transgene expression from replication-defective vectors (Ad-GFP, Ad-Luc) , 2002, Cancer Gene Therapy.

[21]  M. Halterman,et al.  A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  R. Martuza,et al.  Replication-selective virotherapy for cancer: Biological principles, risk management and future directions , 2001, Nature Medicine.

[23]  R. D'Amato,et al.  Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  L. Johnson,et al.  An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy , 2000, Nature Medicine.

[25]  T. Hermiston.  Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer. , 2000, The Journal of clinical investigation.

[26]  E. Harlow,et al.  Cellular targets for transformation by the adenovirus E1A proteins , 1989, Cell.

[27]  G. Winberg,et al.  Dissection of overlapping functions within the adenovirus type 5 E1A gene. , 1984, The EMBO journal.

[28]  Xian-Yang Zhang,et al.  LSU Digital Commons LSU Digital Commons Altering the tropism of lentiviral vectors through pseudotyping Altering the tropism of lentiviral vectors through pseudotyping , 2022 .